Brief: Moberg Pharma Comments On The Results Of The North American Phase 3 Study With Mob-015

Moberg Pharma AB (publ)

12/12/2019 07:10

Dec 12 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * MOBERG PHARMA COMMENTS ON THE RESULTS OF THE NORTH
AMERICAN
PHASE 3 STUDY WITH MOB-015
    * FACT THAT MOB-015 ACHIEVED MYCOLOGICAL CURE IN 70 PERCENT
OF
PATIENTS IN THIS STUDY IS EXCEPTIONAL AND EXCEEDED EXPECTATIONS 
    * MOB-015 SIGNIFICANTLY OUTPERFORMED VEHICLE FOR KEY
ENDPOINTS AND
CONFIRMED ABILITY TO RAPIDLY ACHIEVE VISIBLE IMPROVEMENT 
    * EXPECTS FURTHER INSIGHT FROM ONGOING EUROPEAN STUDY, WHERE
MOB-015 IS BEING COMPARED TO MOST COMMONLY USED TOPICAL
TREATMENT 
    * ON MONDAY TOPLINE RESULTS WERE PRESENTED FROM FIRST STUDY
IN
PHASE 3 PROGRAM FOR MOB-015, WHERE PRIMARY ENDPOINT AND TWO KEY
SECONDARY ENDPOINTS WERE MET

Source text for Eikon:  ID:nWkr542dK9 
Further company coverage:  MBPH.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))